Zorn SH - Search Results

1

Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D4 receptor antagonist.

Sanner MA, Chappie TA, Dunaiskis AR, Fliri AF, Desai KA, Zorn SH, Jackson ER, Johnson CG, Morrone JM, Seymour PA, Majchrzak MJ, Faraci WS, Collins JL, Duignan DB, Prete Di CC, Lee JS, Trozzi A. Sanner MA, et al. Among authors: zorn sh. Bioorg Med Chem Lett. 1998 Apr 7;8(7):725-30. doi: 10.1016/s0960-894x(98)00108-5. Bioorg Med Chem Lett. 1998. PMID: 9871530

2

A new class of selective and potent inhibitors of neuronal nitric oxide synthase.

Lowe JA 3rd, Qian W, Volkmann RA, Heck S, Nowakowski J, Nelson R, Nolan C, Liston D, Ward K, Zorn S, Johnson C, Vanase M, Faraci WS, Verdries KA, Baxter J, Doran S, Sanders M, Ashton M, Whittle P, Stefaniak M. Lowe JA 3rd, et al. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2569-72. doi: 10.1016/s0960-894x(99)00432-1. Bioorg Med Chem Lett. 1999. PMID: 10498210

3

3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.

Howard HR, Lowe JA 3rd, Seeger TF, Seymour PA, Zorn SH, Maloney PR, Ewing FE, Newman ME, Schmidt AW, Furman JS, Robinson GL, Jackson E, Johnson C, Morrone J. Howard HR, et al. Among authors: zorn sh. J Med Chem. 1996 Jan 5;39(1):143-8. doi: 10.1021/jm950625l. J Med Chem. 1996. PMID: 8568801

4

The discovery of potent and selective dopamine D4 receptor antagonists.

Faraci WS, Zorn SH, Sanner MA, Fliri A. Faraci WS, et al. Among authors: zorn sh. Curr Opin Chem Biol. 1998 Aug;2(4):535-40. doi: 10.1016/s1367-5931(98)80131-2. Curr Opin Chem Biol. 1998. PMID: 9736928 Review.

5

Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition.

Mansbach RS, Brooks EW, Sanner MA, Zorn SH. Mansbach RS, et al. Among authors: zorn sh. Psychopharmacology (Berl). 1998 Jan;135(2):194-200. doi: 10.1007/s002130050501. Psychopharmacology (Berl). 1998. PMID: 9497025

6

5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists.

Lowe JA 3rd, Hageman DL, Drozda SE, McLean S, Bryce DK, Crawford RT, Zorn S, Morrone J, Bordner J. Lowe JA 3rd, et al. J Med Chem. 1994 Oct 28;37(22):3789-811. doi: 10.1021/jm00048a015. J Med Chem. 1994. PMID: 7966138

7

Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor.

McLean S, Ganong A, Seymour PA, Bryce DK, Crawford RT, Morrone J, Reynolds LS, Schmidt AW, Zorn S, Watson J, Fossa A, DePasquale M, Rosen T, Nagahisa A, Tsuchiya M, Heym J. McLean S, et al. J Pharmacol Exp Ther. 1996 May;277(2):900-8. J Pharmacol Exp Ther. 1996. PMID: 8627572

8

The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1- azabicyclo[2.2.2]-octan-3-amine as a novel, nonpeptide substance P antagonisst.

Lowe JA 3rd, Drozda SE, Snider RM, Longo KP, Zorn SH, Morrone J, Jackson ER, McLean S, Bryce DK, Bordner J, et al. Lowe JA 3rd, et al. Among authors: zorn sh. J Med Chem. 1992 Jul 10;35(14):2591-600. doi: 10.1021/jm00092a009. J Med Chem. 1992. PMID: 1378901

9

1-(2-Aminoethyl)-3-methyl-8,9-dihydropyrano[3,2-e]indole: a rotationally restricted phenolic analog of the neurotransmitter serotonin and agonist selective for serotonin (5-HT2-type) receptors.

Macor JE, Fox CB, Johnson C, Koe BK, Lebel LA, Zorn SH. Macor JE, et al. Among authors: zorn sh. J Med Chem. 1992 Oct 2;35(20):3625-32. doi: 10.1021/jm00098a005. J Med Chem. 1992. PMID: 1433172

10

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.

Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al. Seeger TF, et al. Among authors: zorn sh. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13. J Pharmacol Exp Ther. 1995. PMID: 7562537

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45 results

Search Page